State Variation in AIDS Drug Assistance Program Prescription Drug Coverage for Modifiable Cardiovascular Risk Factors
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
In the United States, mortality from cardiovascular disease has become increasingly common among HIV-infected persons. One-third of HIV-infected persons in care may rely on state-run AIDS Drug Assistance Programs (ADAPs) for cardiovascular disease-related prescription drugs. There is no federal mandate regarding ADAP coverage for non-HIV medications.
To assess the consistency of ADAP coverage for type 2 diabetes, hypertension, hyperlipidemia, and smoking cessation using clinical guidelines as the standard of care.
Cross-sectional survey of 53 state and territorial ADAP formularies.
ADAPs covering all first-line drugs for a cardiovascular risk factor were categorized as “consistent” with guidelines, while ADAPs covering at least one first-line drug, but not all, for a cardiovascular risk factor, were categorized as “partially consistent”. ADAPs without coverage were categorized as “no coverage”.
Of 53 ADAPs, four (7.5%) provided coverage consistent with guidelines (coverage for all first-line drugs) for all four cardiovascular risk factors. Thirteen (24.5%) provided no coverage for all four risk factors. Thirty-six (68%) provided at least partially consistent coverage for at least one surveyed risk factor. State ADAPs provided coverage consistent with guidelines most frequently for type 2 diabetes (28%), followed by hypertension (25%), hyperlipidemia (15%) and smoking cessation (8%). Statins (66%) were most commonly covered and nicotine replacement therapies (9%) least often. Many ADAPs provided no first-line treatment coverage for hypertension (60%), type 2 diabetes (51%), smoking cessation (45%), and hyperlipidemia (32%).
Consistency of ADAP coverage with guidelines for the surveyed cardiovascular risk factors varies widely. Given the increasing lifespan of HIV-infected persons and restricted ADAP budgets, we recommend ADAP coverage be consistent with guidelines for cardiovascular risk factors.
- Harrison KM, Song R, Zhang X. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr. 2010;53:124–30. CrossRef
- Bhaskaran K, Hamouda O, Sannes M, et al. CASCADE Collaboration. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008;300:51–9. CrossRef
- Centers for Disease Control and Prevention: Persons Aged 50 Years and Older. Available at: http://www.cdc.gov/hiv/topics/over50/index.htm. Accessed June 16, 2011.
- Smith C, Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group Association between modifiable and non-modifiable risk factors and specific causes of death in the HAART era: The Data Collection on Adverse Events of Anti-HIV Drug Study. 16th Conference on Retroviruses and Opportunistic Infections; 2009 Feb 8–11; Montreal, Canada. Abstract 145.
- Mocroft A, Reiss P, Gasiorowski J, et al. Serious fatal and non-fatal non-AIDS-defining illnesses in Europe. Paper presented at: 16th Conference on Retroviruses and Opportunistic Infections; 2009 Feb 8-11; Montreal, Canada. Abstract 707.
- Crum NF, Riffenburgh RH, Wegner S, et al. Triservice AIDS Clinical Consortium. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr. 2006;41:194–200. CrossRef
- Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav. 2010;14:824–35. CrossRef
- Ledergerber B, Furrer H, Rickenbach M, et al. Swiss HIV Cohort Study. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis. 2007;45:111–9. CrossRef
- Kotler DP. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients. J Acquir Immune Defic Syndr. 2008;49:S79-85. CrossRef
- Friis-Moller N, Sabin CA, Weber R, et al. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003. CrossRef
- Friis-Moller N, Reiss P, Sabin CA, et al. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723–35. CrossRef
- The Henry J. Kaiser Family Foundation: HIV/AIDS Policy Fact Sheet: AIDS Drug Assistance Program, April 2009. Available at: http://www.kff.org/hivaids/upload/1584_10.pdf. Accessed June 16, 2011.
- National Alliance of State and Territorial Directors. National ADAP Monitoring Project Annual Report, May 2010. Available at: http://www.nastad.org/Docs/highlight/201053_2010%20National%20ADAP%20Monitoring%20Report.pdf. Accessed June 16, 2011.
- Smith SR, Buchanan RJ. The AIDS drug assistance programs and coverage of HIV-related medications. Ann Pharmacother. 2001;35:155–66. CrossRef
- Bassett IV, Farel C, Szmuilowicz ED, Walensky RP. HIV/AIDS: AIDS Drug Assistance Programs in the era of routine HIV testing. Clin Infect Dis. 2008;47:695–701. CrossRef
- Grol R. Successes and failures in the implementation of evidence-based guidelines for clinical practice. Med Care. 2001;39:II46-54. CrossRef
- Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ. 1999; 318:527–30. CrossRef
- Nathan DM, Buse JB, Davidson MB, et al. American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203. CrossRef
- Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–72. CrossRef
- Cushman WC, Ford CE, Einhorn PT, et al. ALLHAT Collaborative Research Group. Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2008;10:751–60. CrossRef
- National Cholesterol Education Program Third Report of the National Cholesterol Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Final Report. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm. Accessed June 16, 2011.
- 2008 PHS Guideline Update Panel, Liaisons, and Staff. Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary. Respir Care. 2008;53:1217–22.
- National Alliance of State and Territorial AIDS Directors, National ADAP Monitoring Program Annual Report, April 2009. Available at: http://www.nastad.org/Docs/highlight/200946_7861%20FULL%20REPORT%20v3.pdf. Accessed June 16, 2011.
- Centers for Disease Control and Prevention: HIV Surveillance Report, 2008; vol. 20. Available at: http://www.cdc.gov/hiv/surveillance/resources/reports/2008report/. Accessed June 16, 2011.
- Kaiser Family Foundation. The HIV/AIDS Epidemic in the United States. Available at: http://www.kff.org/hivaids/upload/3029-11.pdf. Accessed June 16, 2011.
- Branson BM, Handsfield HH, Lampe MA, et al. Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55:1–17
- Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed June 16, 2011.
- Thompson MA, Aberg JA, Cahn P, et al. International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010; 304:321–33. CrossRef
- Taylor J. National Health Policy Forum. Caring for “Ryan White”: The Fundamentals of HIV/AIDS Treatment Policy. Available at: http://www.nhpf.org/library/background-papers/BP_RyanWhite_08-22-05.pdf. Accessed June 16, 2011.
- Finkelstein R. Ryan White Care Act Reauthorization 2005: Title I and Title II Health Services Expenditures Patterns. Examination of Fiscal Management and the Allocation of CARE Act Resources. New York Academy of Medicine: New York, 2005.
- Choudhry NK, Lee JL, Agnew-Blais J, Corcoran C, Shrank WH. Drug company-sponsored patient assistance programs: a viable safety net? Health Aff (Millwood). 2009;28:827–34. CrossRef
- Drugs for Type 2 Diabetes: Treatment guidelines from the Medical Letter. 2008. Issue 71, p. 47. Available at: http://secure.medicalletter.org/TG-article-71a. Accessed June 16, 2011.
- Carr A, Workman C, Carey D, et al. Rosey Investigators. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet. 2004;363:429–38. CrossRef
- Slama L, Lanoy E, Valantin MA, et al. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antivir Ther. 2008;13:67–76.
- Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356:2457–71. CrossRef
- Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304:411–8. CrossRef
- Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010; 170:1191–201. CrossRef
- Drugs for Lipids. Treatment Guidelines from the Medical Letter. 2008. Issue 66, p. 9. Available at: http://secure.medicalletter.org/TG-article-66a. Accessed June 16, 2011.
- Kastelein JJ, Akdim F, Stroes ES, et al. ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431–43. CrossRef
- Johri M, Paltiel DA, Goldie SJ, Freedberg KA. State AIDS Drug Assistance Programs: equity and efficiency in an era of rapidly changing treatment standards. Med Care. 2002;40:429–41. CrossRef
- State Variation in AIDS Drug Assistance Program Prescription Drug Coverage for Modifiable Cardiovascular Risk Factors
Journal of General Internal Medicine
Volume 26, Issue 12 , pp 1426-1433
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- public assistance
- AIDS drug assistance program
- cardiovascular disease
- Industry Sectors
- Author Affiliations
- 1. Robert Wood Johnson Foundation Clinical Scholars Program, Yale School of Medicine, New Haven, CT, USA
- 2. Department of Veterans Affairs/VA Connecticut Healthcare System, West Haven, CT, USA
- 3. Department of Internal Medicine, Yale School of Medicine, 333 Cedar Street, SHM IE-61, New Haven, CT, 06520-8088, USA
- 4. Department of Investigative Medicine, Yale School of Medicine, New Haven, CT, USA
- 5. Center for Interdisciplinary Research on AIDS, Yale University, New Haven, CT, USA